Citation:Pandya KJ, Dahlberg S, Hidalgo M, Cohen RB, Lee MW, Schiller JH, et al 2007

From Cancer Guidelines Wiki

Citation


Pandya KJ, Dahlberg S, Hidalgo M, Cohen RB, Lee MW, Schiller JH, et al. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2007 Nov;2(11):1036-41 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17975496.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
What is the optimal second-line therapy in patients with extensive stage small cell lung cancer?Associate Professor Michael Michael MBBS(Hons), BSc(Hons), MD, FRACPcompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:What is the optimal second line therapy in patients with extensive stage small cell lung cancer?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal second line therapy in patients with extensive stage small cell lung cancer?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. What is the optimal second-line therapy in patients with extensive stage small cell lung cancer?